INDOCYANINE GREEN- indocyanine green and water Renew Pharmaceuticals Limited

HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use INDOCYANINE GREEN for injection safely and effectively. See full prescribing information for INDOCYANINE GREEN for injection.							
INDOCYANINE GREEN for injection, for intravenous or Initial U.S. Approval: 1959	r interstitial use						
RECENT MAJOR CHA							
Indications and Usage, For determining Cardiac Output, Hepa Removed	atic Function, and Liver Blood Flow (1.1) 12/2024						
Indications and Usage (1.1, 1.2, 1.3)	12/2024						
Dosage and Administration, Indicator-Dilution Studies and He	•						
Removed Dosage and Administration (2.1, 2.2, 2.3, 2.5)	12/2024 12/2024						
INDICATIONS AND U	-						
Indocyanine Green for injection is an optical imaging agent ind							
 Fluorescence imaging of vessels (micro- and macro-vaso before, during and after vascular, gastrointestinal, organ surgeries, including general minimally invasive surgical p aged 1 month and older (1.1) Fluorescence imaging of extrahepatic biliary ducts in adu 	transplant, plastic, micro- and reconstructive rocedures, in adults and pediatric patients						
 older (1.2) Fluorescence imaging of lymph nodes and lymphatic ves cervical and uterine cancer (1.3) 	sels during lymphatic mapping in adults with						
Ophthalmic angiography in adults and pediatric patients	(1.4)						
	STRATION						
• Visualization of vessels, blood flow and tissue perfusion (2.5 mg/mL solution)						
 o 1.25 mg to 5 mg by intravenous injection is recomm pediatric patients aged 1 month and older. o 3.75 mg to 10 mg by intravenous injection is recommextremities through the skin for plastic, micro- and response of the skin for plastic. 	mended for visualization of perfusion in						
o Additional doses may be administered. Do not exce							
 Visualization of extrahepatic biliary ducts in adults and period mg/mL solution) 	ediatric patients aged 12 years and older (2.5						
 o 2.5 mg by intravenous injection at least 45 minutes o Additional doses may be administered. Do not exce 							
Lymphatic mapping of cervical and uterine cancer in adu	lts (1.25 mg/mL solution)						
 o 5 mg interstitially as four 1 mL injections. o See Full Prescribing Information for injection techniq 	ues. (2.3)						
Ophthalmic Angiography							
o Doses up to 40 mg in 2 ml of Sterile Water for Inject	ion by intravenous injection. (2.4)						
See Full Prescribing Information for reconstitution instruct	tions. (2.5).						
DOSAGE FORMS AND ST	TRENGTHS						

For injection: 25 mg of indocyanine green as a lyophilized, green powder for reconstitution in a singlepatient-use vial (3)

----- CONTRAINDICATIONS

Hypersensitivity to indocyanine green (4)

Hypersensitivity reactions: Hypersensitivity reactions including anaphylaxis and urticaria have occurred. Always have cardiopulmonary resuscitation personnel and equipment readily available and monitor patients. (5.1)

The most common adverse reactions reported are anaphylaxis and urticaria. (6)

To report SUSPECTED ADVERSE REACTIONS, contact Diagnostic Green LLC at 1-844-424-3784 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Interference with Thyroid Radioactive Iodine Uptake Studies: Do not perform radioactive iodine uptake studies for at least one week following the use of Indocyanine Green. (7) See 17 for PATIENT COUNSELING INFORMATION.

Revised: 4/2025

FULL PRESCRIBING INFORMATION: CONTENTS*

1 INDICATIONS AND USAGE

- 1.1 Visualization of Vessels, Blood Flow and Tissue Perfusion
- 1.2 Visualization of Extrahepatic Biliary Ducts
- 1.3 Lymphatic Mapping of Cervical and Uterine Cancer
- 1.4 Ophthalmic Angiography

2 DOSAGE AND ADMINISTRATION

2.1 Indicator-Dilution Studies

2.2 Recommended Dose, Administration and Imaging for Visualization of Extrahepatic Biliary Ducts

2.3 Recommended Dose, Administration and Imaging for Lymphatic Mapping of Cervical and Uterine Cancer

2.4 Recommended Dose and Administration for Ophthalmic Angiography

2.5 Reconstitution Instructions

3 DOSAGE FORMS AND STRENGTHS

4 CONTRAINDICATIONS

5 WARNINGS AND PRECAUTIONS

5.1 Hypersensitivity Reactions

5.2 Interference with Thyroid Radioactive Iodine Uptake Studies

6 ADVERSE REACTIONS

7 DRUG INTERACTIONS

8 USE IN SPECIFIC POPULATIONS

- 8.1 Pregnancy
- 8.2 Lactation
- 8.4 Pediatric Use
- 8.5 Geriatric Use

11 DESCRIPTION

12 CLINICAL PHARMACOLOGY

- 12.1 Mechanism of Action
- 12.2 Pharmacodynamics
- 12.3 Pharmacokinetics

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

14 CLINICAL STUDIES

14.1 Lymphatic Mapping of Cervical and Uterine Cancer

16 HOW SUPPLIED/STORAGE AND HANDLING

17 PATIENT COUNSELING INFORMATION

* Sections or subsections omitted from the full prescribing information are not listed.

FULL PRESCRIBING INFORMATION

1 INDICATIONS AND USAGE

Indocyanine Green for injection is indicated:

1.1 Visualization of Vessels, Blood Flow and Tissue Perfusion

Indocyanine Green is indicated for fluorescence imaging of vessels (micro- and macrovasculature), blood flow and tissue perfusion before, during and after vascular, gastrointestinal, organ transplant, plastic, micro- and reconstructive surgeries, including general minimally invasive surgical procedures in adults and pediatric patients aged 1 month and older.

1.2 Visualization of Extrahepatic Biliary Ducts

Indocyanine Green is indicated for fluorescence imaging of extrahepatic biliary ducts in adults and pediatric patients aged 12 years and older.

1.3 Lymphatic Mapping of Cervical and Uterine Cancer

Indocyanine Green is indicated for fluorescence imaging of lymph nodes and delineation of lymphatic vessels during lymphatic mapping in adults with cervical and uterine cancer for which this procedure is a component of intraoperative management.

1.4 Ophthalmic Angiography

Indocyanine Green is indicated for use in ophthalmic angiography in adults and pediatric patients.

2 DOSAGE AND ADMINISTRATION

2.1 Indicator-Dilution Studies

Dosing

Adults:

The recommended dose of Indocyanine Green for a single image sequence for visualization of vessels, blood flow and tissue perfusion in adults is 1.25 mg to 5 mg administered intravenously as 0.5 mL to 2 mL of a 2.5 mg/mL solution.

For visualization of perfusion in extremities through the skin in adults, the recommended dose is 3.75 mg to 10 mg administered intravenously as 1.5 mL to 4 mL of a 2.5 mg/mL solution.

Immediately flush with a 10 mL bolus of 0.9% Sodium Chloride Injection.

Pediatric patients aged 1 month and older:

The recommended dose of Indocyanine Green for a single image sequence for visualization of vessels, blood flow and tissue perfusion in pediatric patients aged 1 month and older is 1.25 mg to 5 mg administered intravenously as 0.5 mL to 2 mL of a 2.5 mg/mL solution. Lower doses may be administered in younger patients and in those with lower body weight. Adjust the amount and type of flush to avoid volume and/or sodium overload.

In both adults and pediatric patients aged 1 month and older, additional doses may be administered to obtain imaging sequences during the procedure. Do not exceed the maximum total dose of 2 mg/kg.

Administration

Prior to the imaging procedure, draw up the desired dose of Indocyanine Green solution into appropriate syringes and prepare a 10 mL syringe of 0.9% Sodium Chloride Injection.

Administer via a central or peripheral venous line using a three-way stopcock attached to an injection port on the infusion line. Inject the prepared Indocyanine Green into the line as a tight bolus. Immediately switch the access on the stopcock and inject the prepared flush.

Imaging Instructions

Indocyanine Green may be used with an FDA-authorized imaging device that is intended to be used with indocyanine green for fluorescence imaging of vessels, blood flow and tissue perfusion.

A fluorescence response should be visible in blood vessels within 5 seconds to 15 seconds after injection.

2.2 Recommended Dose, Administration and Imaging for Visualization of Extrahepatic Biliary Ducts

Dosing and Administration

The recommended dose of Indocyanine Green for visualization of extrahepatic biliary ducts in adults and pediatric patients aged 12 years and older is 2.5 mg administered intravenously as 1 mL of a 2.5 mg/mL solution at least 45 minutes prior to surgery.

Additional doses may be administered to obtain imaging sequences during the procedure.

Do not exceed a total dose of 2 mg/kg.

Imaging Instructions

Indocyanine Green may be used with an FDA-authorized imaging device that is intended to be used with indocyanine green for fluorescence imaging of extrahepatic biliary ducts.

Fluorescence is visible in the biliary tree within 45 minutes after injection.

2.3 Recommended Dose, Administration and Imaging for Lymphatic Mapping of Cervical and Uterine Cancer

Dosing and Administration

The recommended dose of Indocyanine Green for lymphatic mapping of cervical and uterine cancer in adults is 5 mg administered interstitially as four 1 mL injections of a 1.25 mg/mL solution into the cervix, at the 3 o' clock and the 9 o'clock positions with a superficial (1 mm to 3 mm) and a deep (1 cm to 3 cm) injection at each position.

Imaging Instructions

Indocyanine Green may be used with an FDA-authorized imaging device that is intended to be used with indocyanine green for fluorescence imaging of lymph nodes and delineation of lymphatic vessels during lymphatic mapping of cervical and uterine cancer.

Fluorescent lymphatic vessels and lymph nodes should begin to be visible within 1 minute after injection.

2.4 Recommended Dose and Administration for Ophthalmic Angiography

Dosing and Administration

Doses up to 40 mg Indocyanine Green in 2 mL of Sterile Water for Injection depending on the imaging equipment and technique used should be administered intravenously and immediately followed by a 5 mL bolus of 0.9% Sodium Chloride Injection. The antecubital vein can be used for Indocyanine Green administration.

2.5 Reconstitution Instructions

<u>General</u>

- Prepare Indocyanine Green for injection using aseptic techniques prior to procedure.
- Inspect the reconstituted solution for particulate matter. The reconstituted solution should be a clear, green solution.
- Use the prepared solution within 6 hours.
- Discard any unused product.

Visualization of Vessels, Blood Flow, Tissue Perfusion and Extrahepatic Biliary Ducts

Dissolve 25 mg of Indocyanine Green with 10 mL Sterile Water for Injection to form a concentration of 2.5 mg/mL indocyanine green.

Lymphatic Mapping of Cervical and Uterine Cancer

Dissolve 25 mg of Indocyanine Green with 20 mL Sterile Water for Injection to form a concentration of 1.25 mg/mL indocyanine green.

Ophthalmic Angiography

Dissolve doses up to 40 mg of Indocyanine Green with 2 mL Sterile Water for Injection.

3 DOSAGE FORMS AND STRENGTHS

For injection: 25 mg of indocyanine green as a sterile, lyophilized, green powder for reconstitution provided in a 25 mL single-patient-use vial.

4 CONTRAINDICATIONS

Indocyanine Green is contraindicated in patients with a history of hypersensitivity to indocyanine green. Reactions have included anaphylaxis [see Warnings and Precautions (5.1)].

5 WARNINGS AND PRECAUTIONS

5.1 Hypersensitivity Reactions

Hypersensitivity reactions including anaphylaxis, urticaria and deaths due to anaphylaxis have been reported following intravenous administration of Indocyanine Green [see Adverse Reactions (6)].

Indocyanine Green is contraindicated in patients with a history of hypersensitivity to indocyanine green [see Contraindications (4)]. Always have cardiopulmonary resuscitation personnel and equipment readily available and monitor all patients for hypersensitivity reactions.

5.2 Interference with Thyroid Radioactive Iodine Uptake Studies

Because Indocyanine Green contains sodium iodide, the iodine-binding capacity of thyroid tissue may be reduced for at least one week following administration [see Drug Interactions (7)].

6 ADVERSE REACTIONS

The following clinically significant adverse reactions are described elsewhere in the labeling:

• Hypersensitivity Reactions [see Warnings and Precautions (5.1)].

The following adverse reactions have been identified during post-approval use of Indocyanine Green. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Immune System Disorders: Anaphylaxis, urticaria

7 DRUG INTERACTIONS

Interference with Thyroid Radioactive Iodine Uptake Studies

Because Indocyanine Green contains sodium iodide, the iodine-binding capacity of thyroid tissue may be reduced for at least one week following administration. Do not perform radioactive iodine uptake studies for at least one week following administration of Indocyanine Green.

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Risk Summary

There are no adequate and well-controlled studies of Indocyanine Green in pregnant women. Available data from a very small number of scientific literature studies with indocyanine green use in pregnant women over several decades have not reported any drug associated risks for major birth defects, miscarriage, or adverse maternal or fetal outcomes. Data from one small study in which indocyanine green was administered intravenously to pregnant women during labor suggest there is no placental transfer of the drug. Animal reproduction studies have not been conducted with indocyanine green.

All pregnancies have a background risk of birth defects, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.

8.2 Lactation

Risk Summary

Seventeen cases of indocyanine green use in lactating women have been reported in the scientific literature with no adverse events observed in the breastfed infant. However, there are no data on the presence of indocyanine green in human milk or the effects on milk production. Therefore, the developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for Indocyanine Green and any potential adverse effects on the breastfed infant from Indocyanine Green or from the underlying maternal condition.

8.4 Pediatric Use

Use of Indocyanine Green for visualization of vessels, blood flow and tissue perfusion has been established in pediatric patients aged 1 month and older. Pediatric use is supported by published data in 49 pediatric patients who received indocyanine green for assessment of blood flow and tissue perfusion in cardiovascular, vascular, and plastic, micro- and reconstructive surgical procedures, and by clinical trials in adults. No overall differences in safety or effectiveness have been observed between pediatric patients and adults. The dose range was similar to the effective dose range in adults [see Dosage and Administration (2.1)]. The use of Indocyanine Green for visualization of vessels, blood flow and tissue perfusion has not been established in pediatric patients aged less than 1 month.

Use of Indocyanine Green for visualization of extrahepatic biliary ducts has been established in pediatric patients aged 12 years and older. Pediatric use is supported by clinical trials in adults in addition to clinical use in pediatric patients. No overall differences in safety or effectiveness have been observed between pediatric patients and adults. The dose range was similar to the effective dose range in adults *[see Dosage and Administration (2.2)]*. The use of Indocyanine Green for visualization of extrahepatic biliary ducts has not been established in pediatric patients aged less than 12 years.

Use of Indocyanine Green for visualization of lymph nodes and lymphatic vessels during lymphatic mapping for cervical and uterine cancer have not been established in pediatric patients.

Use of Indocyanine Green for ophthalmic angiography has been established in pediatric patients. Pediatric use is supported by evidence from the published literature.

8.5 Geriatric Use

Of the total number of patients in clinical studies of indocyanine green for visualization of vessels, blood flow and tissue perfusion, 7% were 65 and over, while 1% were 75 and over. Of the total number of patients in clinical studies of indocyanine green for visualization of lymph nodes and lymphatic vessels during lymphatic mapping of cervical and uterine cancer, 9% were 65 and over, while 2% were 75 and over. Clinical studies of indocyanine green for visualization of extrahepatic biliary ducts did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently from younger patients.

No overall differences in safety or effectiveness were observed between these patients and younger patients, and other reported clinical experience has not identified differences in responses between elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal or cardiac function, and of concomitant disease or other drug therapy.


11 DESCRIPTION

Indocyanine Green for injection is an optical imaging agent for intravenous or interstitial use.

Each vial contains 25 mg of indocyanine green with not more than 5% sodium iodide as a sterile, lyophilized, green powder. Indocyanine Green has a pH of 5.5-7.5 when reconstituted with Sterile Water for Injection, USP.

The chemical name for Indocyanine Green is 1 *H*Benz[e]indolium, 2-[7-[1,3-dihydro-1,1-dimethyl-3-(4- sulfobutyl)-2*H*-benz[e]indol-2-ylidene]-1,3,5-heptatrienyl]-1,1-dimethyl-3-(4-sulfobutyl)-, hydroxide, inner salt, sodium salt.

Molecular Formula: C43H47N2NaO6S2; Molecular Mass: 774.96 g/mol, with the following structural formula:



Indocyanine green has a peak spectral absorption at 805 nm in blood.

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

When bound to proteins in plasma or in lymph fluid, indocyanine green absorbs light in the near-infrared region with peak absorption at 805 nm and emits fluorescence (light) at a slightly longer wavelength, with peak emission at 830 nm. Fluorescence imaging devices provide external energy as near infrared light for indocyanine green to absorb, resulting in excitation of the indocyanine green, and the emitted light (fluorescence) is transferred from the field of view to an image on a monitor. These optical properties of indocyanine green are utilized in fluorescence imaging of the micro- and macrovasculature, blood flow and tissue perfusion, the extrahepatic biliary ducts, and for lymphatic mapping of lymph nodes and lymphatic vessels.

12.2 Pharmacodynamics

There are no pharmacodynamic data.

12.3 Pharmacokinetics

Distribution

Following intravenous injection, indocyanine green binds to plasma proteins (98%) and is largely confined to the intravascular compartment. Indocyanine green undergoes no significant extrahepatic or enterohepatic circulation; simultaneous arterial and venous blood estimations have shown negligible renal, peripheral, lung or cerebro-spinal uptake of the dye. After biliary obstruction, the dye appears in the hepatic lymph, independently of the bile, suggesting that the biliary mucosa is sufficiently intact to prevent diffusion of the dye, though allowing diffusion of bilirubin.

Following interstitial injection, indocyanine green binds to proteins in lymph fluid and the interstitial space, is taken up by the lymphatic vessels, and drains to the lymph nodes.

Since excessive dye extravasation does not take place in the highly fenestrated choroidal vasculature, Indocyanine Green is useful in both absorption and fluorescence infrared angiography of the choroidal vasculature when using appropriate filters and film in a fundus camera.

Elimination

Indocyanine green is taken up from the plasma almost exclusively by the hepatic parenchymal cells and is secreted entirely into the bile.

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

No studies have been performed to evaluate the potential for carcinogenicity, mutagenicity, or impairment of fertility by indocyanine green.

14 CLINICAL STUDIES

14.1 Lymphatic Mapping of Cervical and Uterine Cancer

The effectiveness of Indocyanine Green for fluorescence imaging of lymph nodes and delineation of lymphatic vessels during lymphatic mapping in adults with cervical and uterine cancer has been established based on a study of another formulation of indocyanine green for injection. Below is a description of the FILM Study (NCT 02209532).

The study was a randomized, prospective, multi-center, open-label study in patients with early stage uterine or cervical cancer and no known regional nodal or metastatic disease by standard clinical evaluation. Indocyanine green and a blue dye comparator were injected into the cervix of patients at the beginning of the operative procedure.

A total of 176 patients were randomized to receive either indocyanine green followed by blue dye or blue dye followed by indocyanine green. A total of four 1 mL injections of a 1.25 mg/ml solution of indocyanine green for a total dose of 5 mg were administered interstitially into the cervix at the 3 o'clock and 9 o'clock positions with a superficial (1 mm to 3 mm) and a deep (1 cm to 3 cm) injection at each position.

Lymphatic mapping was performed intraoperatively using a fluorescence imaging device and standard light, followed by excision of tissues identified by indocyanine green, blue dye, or the surgeon's visual and palpation examination. The resected tissues were evaluated by histopathology to confirm presence of lymph nodes. The efficacy of indocyanine green in the detection of lymphatic vessels and lymph nodes during lymphatic mapping procedures was determined by the number of histology-confirmed lymph nodes detected by indocyanine green and/or the blue dye comparator.

The mean age of the 176 patients was 63 years (range: 31 to 88 years); distribution by race and ethnicity was 79% White, 4% Black or African American, 3% Asian, 13% Hispanic/Latino and 1% other.

Table 1 shows the distribution of resected, confirmed lymph nodes detected by indocyanine green or blue dye in the modified intent-to-treat population (mITT). Among the confirmed lymph nodes identified, 93% were identified using indocyanine green, and 43% were identified using blue dye, a difference of 50% [95% confidence interval 39% to 60%].

Table 1: Distribution of Resected, Confirmed Lymph Nodes Detected by						
Indocyanine Green or Blue Dye (BD)						

Analysis Population		All Lymph Nodes Detected with Indocyanine Green	IDATACTAC	Lymph Nodes Detected with Indocyanine Green Only	Lymph Nodes Detected with BD Only	Lymph Nodes Detected with Neither
mITT	513	(476/513)	(220/513)	(262/513)	(6/513)	(31/513)
		93%	43%	51%	1%	6%

Table 2 shows the number of patients with at least one resected, confirmed lymph node and the number of patients with at least one bilateral lymph node pair detected by indocyanine green or blue dye. With indocyanine green, approximately 97% of patients had at least one resected, confirmed lymph node detected and 73% had at least one bilateral lymph node pair detected, compared with 68% and 28%, respectively, with blue dye (p-values for each analysis <0.0001).

Table 2: Distribution of Patients with at Least One Confirmed Unilateral Lymph Node/ Bilateral Pair Detected by Indocyanine Green or Blue Dye (BD)

Analysis Population	Patients (n)	Patients with All Lymph Nodes Detected with Indocyanine Green	Patients with All Lymph Nodes Detected with BD	Patients with Lymph Nodes Detected with Indocyanine Green only		Patients with Lymph Nodes Detected with Neither
mITT	172	(167/172)	(118/172)	(51/172)	(2/172)	(3/172)
Unilateral*		97%	68%	30%	1%	3%
mITT		(126/172)	(49/172)	(79/172)	(2/172)	(44/172)
Bilateral**		73%	28%	46%	1%	26%

*: patients with at least one resected confirmed lymph node detected unilaterally **: patients with at least one resected confirmed lymph node detected bilaterally

16 HOW SUPPLIED/STORAGE AND HANDLING

How Supplied

Indocyanine Green for injection is supplied as a kit (NDC 70100-424-02) containing the following:

- Six 25 mL single-patient-use vials of Indocyanine Green (25 mg each) as a sterile, lyophilized green powder for reconstitution NDC 70100-424-01
- Six single-dose vials of Sterile Water for Injection (10 mL each) NDC 63323-185-10 or NDC 0409-4887-17 or NDC 0641-6147-01.

Storage and Handling

Store at 20°C to 25°C (68°F to 77°F).

17 PATIENT COUNSELING INFORMATION

Hypersensitivity Reactions

Advise patients to seek medical attention for reactions following injection of Indocyanine Green such as difficulty breathing, swollen tongue or throat, skin reactions including hives, itching and flushed or pale skin, low blood pressure, a weak and rapid pulse and other symptoms or signs of an anaphylactic reaction [see Warnings and Precautions (5.1)].

Manufactured by:

Patheon Italia S.p.A. 20900 Monza (MB), ITALY

or

LYOCONTRACT GmbH 38871 Ilsenburg, GERMANY

Distributed by:

Diagnostic Green LLC Farmington Hills, MI 48331

Sterile Water for injection, USP is manufactured by:

Fresenius Kabi USA, LLC Grand Island, NY 14072

or

Hospira, Inc. Rocky Mount, NC 27804

or

Hikma Pharmaceuticals USA Inc. Cherry Hill, NJ 08003

50426

PRINCIPAL DISPLAY PANEL - Vial



Rx only Sterile

Indocyanine Green for Injection, USP

25 mg/Vial

Single-Patient-Use For Intravenous or Interstitial Use


After reconstitution, use within 6 hours.

Distributed by: Diagnostic Green LLC

50428 01/2025

Lot No. Exp.:

PRINCIPAL DISPLAY PANEL - STERILE WATER VIAL



10 mL Single-dose

Sterile Water

for Injection, USP

FOR DRUG DILUENT USE

Rx only NDC 0409-4887-17

Contains no antimicrobial or other added

substance. Sterile, nonpyrogenic. Do not give intravenously unless rendered nearly isotonic.

Hospira, Inc. RL-4428 Lake Forest, IL 60045 USA

PRINCIPAL DISPLAY PANEL - Carton



Carton Label

NDC 70100-424-02

Rx Only - Sterile

Indocvanine Green for Injection, USP 25 mg/Vial

Single-Patient-Use

For Intravenous or Interstitial Use

Distributed by: Diagnostic Green LLC

Back Panel

NDC 70100-424-02 Rx Only - Sterile

Recommended Dosage and Reconstitution Instructions: See Prescribing Information Use within 6 hours after reconstitution.

STORAGE: Store at 20° to 25° C (68° to 77°F)

KIT CONTAINS:

- Six vials of Indocyanine Green (25 mg each)
- Six Sterile Water for Injection (10 mL each)

Indocyanine Green for Injection, USP 25 mg/Vial

Single-Patient-Use

For Intravenous or Interstitial Use

Left Panel

Indocvanine Green for Injection, USP

Distributed by: Diagnostic Green LLC Farmington Hills MI 48331 USA

Manufactured by: Patheon Italia S.p.A. 20052 Monza (Milano) ITALY

or Lyocontract GmbH

38871 Ilsenburg GERMANY

Sterile Water Manufactured by: Hospira, Inc. Rocky Mount, NC 27804 or Fresenius Kabi USA, LLC Grand Island, NY 14072 or Hikma Pharmaceuticals Berkeley Heights, NJ 07922

01/2025

INDOCYANINE GREEN indocyanine green and water kit							
	locyanine gree						
Ρ	roduct Infor	mation					
Ρ	roduct Type	HUMAN PRI	ESCRIPTION DRUG	lter	n Code (Source)	NDC:70100-424	
Ρ	ackaging						
#	ltem Code	Pa	kage Description	1	Marketing Start Date	Marketing End Date	
1	NDC:70100-424- 02	6 in 1 CARTON	I		01/01/2008		
1		1 in 1 PACKAG Product	E; Type 0: Not a Comb	ination			
Q	uantity of Pa	arts					
P	art #	Package C	uantity		Total Product Qu	antity	
Pa	art 1 1 VIAL			1			
Pa	art 2 1 VIAL, PLA	STIC		10 mL			
Part 1 of 2							
INDOCYANINE GREEN							
indocyanine green injection, powder, lyophilized, for solution							
P	Product Information						
R	Route of Administration INTRAVENOUS, INTERSTITIAL						

Active Ingred	lient/Active	Moiety				-		
	Ing	gredient Name			Basis Streng	STron(
INDOCYANINE GF UNII:C4V974V932)	REEN (UNII: IX6J1	063HV) (INDOCYANINE GREEN A	ACID FORM -		OCYANIN EEN	E 25 mg		
Packaging								
# Item Code	Packa	ge Description	Marketing Dat		Mark	ceting End Da		
	in 1 VIAL; Type roduct	0: Not a Combination						
Marketing	Informat	ion						
Marketing Category	Applica	tion Number or Monogra Citation	ph Mark	eting S ^r Date	tart	Marketing End Date		
ANDA	ANDA04081	1	01/01/2	008				
Part 2 of 2								
STERILE W	ΔTFR							
water injection								
,,				_	_			
Product Info	rmation							
ltem Code (Soເ	urce)	NDC:0409-4887						
Route of Admir	nistration	INTRAVENOUS, INTERSTITIAL						
Active Ingred	lient/Active	Moiety						
	Ingredie	ent Name	Basi	is of Sti	ength	Strength		
NATER (UNII: 059	QF0KO0R) (WATE	R - UNII:059QF0KO0R)	WATER			1 mL in 1 mL		
Packaging								
# Item Code	Pa	ckage Description	Mark	eting S Date	tart	Marketing En Date		
1 NDC:0409- 4887-17	10 mL in 1 VIAL Combination Pr	., PLASTIC; Type 0: Not a						
Marketing	Informat	ion						
Marketing		tion Number or Monogra	ph Mark	eting S	tart	Marketing En		
Category		Citation		Date		Date		

NDA	NDA018801	10/27/1982				
Marketing Information						
Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date			
ANDA	ANDA040811	01/01/2008				

Labeler - Renew Pharmaceuticals Limited (985716301)

Establishment

Name	Address	ID/FEI	Business Operations
Umforana Labor für Umweltanalytik und Auftragsforschung GmbH $\&$ Co. KG		340876986	ANALYSIS(70100-424)

Revised: 4/2025

Renew Pharmaceuticals Limited